China Steps Up Oversight Of Value-adding Services
This article was originally published in PharmAsia News
China's State FDA recently requested that its regional branches accelerate inspections and oversight of domestic pharma value-adding services for foreign businesses
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.
The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.